EarleFBurgessMD

PubMed

• 29 citations
  Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
  Elisa Ledet, Earle F. Burgess, Alexandra O. Sokolova, Ellen Jaeger, Whitley Hatton
  The Prostate. 2021-05-01
• 16 citations
  Management changes for patients with endocrine-related cancers in the COVID-19 pandemic.
  Derek Raghavan, Antoinette R. Tan, E. Shannon Story, Earle F. Burgess, Laura W. Musselwhite
  Endocrine-Related Cancer. 2020-09-01
• 758 citations
  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
  Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert Huddart
  The New England Journal of Medicine. 2019-07-24

Journal Articles

• Individualized Management of Advanced Bladder Cancer: Where Do We Stand?  
  Burgess EF, Urologic Oncology, 1/1/2015
• Prostate Cancer: What Did We Learn from the 2012 Annual Tumors-What Have We Learned in 35 Years?  
  Riggs S, Burgess EF, Gaston D, Raghavan D, Oncologist, 1/1/2014
• Prostate Cancer Serum Biomarker Discovery Through Proteomic Analysis of Alpha-2 Macroglobulin Protein Complexes  
  Burgess EF, Ham AL, Tabb DL et al, Proteomics-Clinical Applications, 1/1/2008
• Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer  
  Burgess EF and Roth BJ, Urol Clin. North Am., 1/1/2006
• Join now to see all

Books/Book Chapters

• Cancer Medicine 
  Chapter: Urothelial Cancer 
  Raghavan D, Cote R, Burgess EF, Riggs S and Haake MJohn Wiley and Sons, Inc., Hoboken, NJEdition 9th,2017
• Cancer Medicine 
  Chapter: Renal Cell Carcinoma 
  Burgess EF, Riggs SB, Rini BI and Raghavan DJohn Wiley and Sons, Inc., Hoboken, NJEdition 9th,2017
• Textbook of Uncommon Cancer 
  Chapter: Penile Carcinoma 
  Mark JR, Riggs SB, Graham DL, McHaffie DR, Livasy CA and Burgess EFJohn Wiley and Sons, Ltd., Chichester, UKEdition 5th,2017

Abstracts/Posters

• Molecular profiles of small cell bladder and prostate cancer and comparisons with small cell lung cancer.
  Dawson N, Geynisman D, Burgess E, Somer B, Arguello D, Hauke R, Vaena D, Raghavan D, Heath E, J Clin Oncol, 1/1/2018
• Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor inhibitor, in patients with metastatic or unresectable urothelial carcinoma and FGFR alterati...
  Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, OHagan A, Avadhani A, Zhong B, Stuyc..., Clin Oncol, 1/1/2018
• Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis o...
  Siefker-Radtke A, Necchi A, Rosenbaum E, Culine S, Burgess E, O'Donnell P, Tagawa S, Zakharia Y, OHagan A, Avadhani A, Zhong B, Santiago-Walker A, Roccia T, Loriot Y, J Clin Oncol, 1/1/2018
• Discordance Rate of PD-L1 Expression Between Primary and Metastatic Lesions in Urothelial Carcinoma.
  Burgess E, Naso C, Doherty S, Guerrieri R, Livasy C, Hartmann A, Robinson M, Symanowski J, Grigg C, Graham D, Osei-Boateng K, Riggs S, Clark P, Raghavan D, J Clin Oncol, 1/1/2018
• Impact of Local Intervention (Surgery/Radiation) in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors Stratified by Heng Criteria.
  Merwarth CA, Amin A, Han Y, Symanowski JT, Burgess EF, Gaston KE, Riggs SB, J Clin Oncol, 1/1/2015
• Observations from Early Adoption of Radium 223 in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer.
  McHaffie DR, Sharp HJ, Symanowski J, Crimaldi AJ, Mahoney J, Burgess EF, Nazemzadeh R and Haake MR, Int J Radiat Oncol Biol Phys, 1/1/2014
• Join now to see all

Lectures

• A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018